Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age

Syoichiro Kono, Kentaro Deguchi, Nobutoshi Morimoto, Tomoko Kurata, Toru Yamashita, Yoshio Ikeda, Hisashi Narai, Yasuhiro Manabe, Yoshiki Takao, Sanami Kawada, Kenichi Kashihara, Yasushi Takehisa, Satoshi Inoue, Hideki Kiriyama, Koji Abe

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Alteplase, a recombinant tissue plasminogen activator (tPA), was approved for patients with acute ischemic stroke within 3 hours of stroke onset in Japan in October 2005 at a dose of 0.6 mg/kg. The aim of this study was to assess the safety and efficacy of alteplase in elderly patients in Japan. Methods: One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (80 years of age [older group]) and by treatment with or without edaravone. Clinical backgrounds and outcomes were investigated. Results: The National Institutes of Health Stroke Scale score on admission was not different in both groups, but the National Institutes of Health Stroke Scale scores 7 days after stroke onset were significantly higher in the older group (score 8; P

Original languageEnglish
Pages (from-to)1175-1183
Number of pages9
JournalJournal of Stroke and Cerebrovascular Diseases
Volume22
Issue number7
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Stroke
Tissue Plasminogen Activator
National Institutes of Health (U.S.)
Japan
Therapeutics
Age Groups
phenylmethylpyrazolone
Safety

Keywords

  • Acute ischemic stroke
  • edaravone
  • elderly
  • intracerebral hemorrhage
  • recanalization
  • tissue plasminogen activator

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Rehabilitation
  • Cardiology and Cardiovascular Medicine

Cite this

Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. / Kono, Syoichiro; Deguchi, Kentaro; Morimoto, Nobutoshi; Kurata, Tomoko; Yamashita, Toru; Ikeda, Yoshio; Narai, Hisashi; Manabe, Yasuhiro; Takao, Yoshiki; Kawada, Sanami; Kashihara, Kenichi; Takehisa, Yasushi; Inoue, Satoshi; Kiriyama, Hideki; Abe, Koji.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 22, No. 7, 10.2013, p. 1175-1183.

Research output: Contribution to journalArticle

Kono, S, Deguchi, K, Morimoto, N, Kurata, T, Yamashita, T, Ikeda, Y, Narai, H, Manabe, Y, Takao, Y, Kawada, S, Kashihara, K, Takehisa, Y, Inoue, S, Kiriyama, H & Abe, K 2013, 'Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age', Journal of Stroke and Cerebrovascular Diseases, vol. 22, no. 7, pp. 1175-1183. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.02.010
Kono, Syoichiro ; Deguchi, Kentaro ; Morimoto, Nobutoshi ; Kurata, Tomoko ; Yamashita, Toru ; Ikeda, Yoshio ; Narai, Hisashi ; Manabe, Yasuhiro ; Takao, Yoshiki ; Kawada, Sanami ; Kashihara, Kenichi ; Takehisa, Yasushi ; Inoue, Satoshi ; Kiriyama, Hideki ; Abe, Koji. / Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. In: Journal of Stroke and Cerebrovascular Diseases. 2013 ; Vol. 22, No. 7. pp. 1175-1183.
@article{6221a09e8fef48a3b25e52234b1f52cc,
title = "Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age",
abstract = "Background: Alteplase, a recombinant tissue plasminogen activator (tPA), was approved for patients with acute ischemic stroke within 3 hours of stroke onset in Japan in October 2005 at a dose of 0.6 mg/kg. The aim of this study was to assess the safety and efficacy of alteplase in elderly patients in Japan. Methods: One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (80 years of age [older group]) and by treatment with or without edaravone. Clinical backgrounds and outcomes were investigated. Results: The National Institutes of Health Stroke Scale score on admission was not different in both groups, but the National Institutes of Health Stroke Scale scores 7 days after stroke onset were significantly higher in the older group (score 8; P",
keywords = "Acute ischemic stroke, edaravone, elderly, intracerebral hemorrhage, recanalization, tissue plasminogen activator",
author = "Syoichiro Kono and Kentaro Deguchi and Nobutoshi Morimoto and Tomoko Kurata and Toru Yamashita and Yoshio Ikeda and Hisashi Narai and Yasuhiro Manabe and Yoshiki Takao and Sanami Kawada and Kenichi Kashihara and Yasushi Takehisa and Satoshi Inoue and Hideki Kiriyama and Koji Abe",
year = "2013",
month = "10",
doi = "10.1016/j.jstrokecerebrovasdis.2013.02.010",
language = "English",
volume = "22",
pages = "1175--1183",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age

AU - Kono, Syoichiro

AU - Deguchi, Kentaro

AU - Morimoto, Nobutoshi

AU - Kurata, Tomoko

AU - Yamashita, Toru

AU - Ikeda, Yoshio

AU - Narai, Hisashi

AU - Manabe, Yasuhiro

AU - Takao, Yoshiki

AU - Kawada, Sanami

AU - Kashihara, Kenichi

AU - Takehisa, Yasushi

AU - Inoue, Satoshi

AU - Kiriyama, Hideki

AU - Abe, Koji

PY - 2013/10

Y1 - 2013/10

N2 - Background: Alteplase, a recombinant tissue plasminogen activator (tPA), was approved for patients with acute ischemic stroke within 3 hours of stroke onset in Japan in October 2005 at a dose of 0.6 mg/kg. The aim of this study was to assess the safety and efficacy of alteplase in elderly patients in Japan. Methods: One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (80 years of age [older group]) and by treatment with or without edaravone. Clinical backgrounds and outcomes were investigated. Results: The National Institutes of Health Stroke Scale score on admission was not different in both groups, but the National Institutes of Health Stroke Scale scores 7 days after stroke onset were significantly higher in the older group (score 8; P

AB - Background: Alteplase, a recombinant tissue plasminogen activator (tPA), was approved for patients with acute ischemic stroke within 3 hours of stroke onset in Japan in October 2005 at a dose of 0.6 mg/kg. The aim of this study was to assess the safety and efficacy of alteplase in elderly patients in Japan. Methods: One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (80 years of age [older group]) and by treatment with or without edaravone. Clinical backgrounds and outcomes were investigated. Results: The National Institutes of Health Stroke Scale score on admission was not different in both groups, but the National Institutes of Health Stroke Scale scores 7 days after stroke onset were significantly higher in the older group (score 8; P

KW - Acute ischemic stroke

KW - edaravone

KW - elderly

KW - intracerebral hemorrhage

KW - recanalization

KW - tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=84886005119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886005119&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2013.02.010

DO - 10.1016/j.jstrokecerebrovasdis.2013.02.010

M3 - Article

VL - 22

SP - 1175

EP - 1183

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 7

ER -